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Abstract
The aim of this study was to investigate the possible reduced risk of Parkinson Disease (PD) due to coffee, alcohol, and/or
cigarette consumption. In addition, we explored the potential effect modification by intensity, duration and time-since-
cessation of smoking on the association between cumulative pack-years of cigarette smoking (total smoking) and PD risk.
Data of a hospital based case-control study was used including 444 PD patients, diagnosed between 2006 and 2011, and
876 matched controls from 5 hospitals in the Netherlands. A novel modeling method was applied to derive unbiased
estimates of the potential modifying effects of smoking intensity, duration, and time-since-cessation by conditioning on
total exposure. We observed no reduced risk of PD by alcohol consumption and only a weak inverse association between
coffee consumption and PD risk. However, a strong inverse association of total smoking with PD risk was observed
(OR= 0.27 (95%CI: 0.18–0.42) for never smokers versus highest quartile of tobacco use). The observed protective effect of
total smoking was significantly modified by time-since-cessation with a diminishing protective effect after cessation of
smoking. No effect modification by intensity or duration of smoking was observed indicating that both intensity and
duration have an equal contribution to the reduced PD risk. Understanding the dynamics of the protective effect of smoking
on PD risk aids in understanding PD etiology and may contribute to strategies for prevention and treatment.
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Introduction
Coffee, alcohol and cigarette consumption are potential
protective factors for the development of Parkinson disease (PD)
[1]. The evidence for an association between cigarette smoking
and PD risk is particularly strong with studies consistently showing
an exposure dependent reduction in risk with total lifetime
exposure to cigarette smoke, the product of (average daily)
smoking intensity and duration of smoking [2–4]. However, it
has been suggested that duration of smoking and time-since-
cessation may be more relevant to PD risk than smoking intensity
[5,6]. Insight into the relative importance of duration, intensity,
and time-since-cessation of cigarette smoking on PD risk may offer
important clues to PD etiology and to strategies for prevention and
treatment [5].
Due to their interrelatedness, modeling independent effects of
duration, intensity and time-since-cessation of smoking on disease
risk is complex. For example, when modeling the duration of
smoking the parameter estimate represents the risk per year of
smoking for a fixed intensity. As such the risks modeled at two
different durations do not only reflect the difference in duration,
but also the difference in total lifetime smoking. To circumvent
this problem Lubin et al. described a model in which the
modifying effects of intensity or duration can be investigated by
conditioning the model on total exposure, allowing a comparison
of the risk of low intensity exposures at long duration with risk of
high intensity exposures at short duration [7]. Recently, this
method was extended by including a term for time-since-cessation
of smoking [8].
In a recently conducted hospital based case-control study we
assessed the potential protective effect of coffee, alcohol and
cigarette consumption on PD risk. The protective effect of
cigarette smoking on PD risk was further explored by investigating
the independent contribution of duration, intensity and time-since-
cessation of smoking.
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Materials and Methods
Ethics statement
The study was approved by the Medical Ethics Committee of St
Elisabeth Hospital Tilburg, the Netherlands. All participants gave
written informed consent.
Cases and controls
Cases and controls were recruited between April 2010 and June
2012 from 5 hospitals in 4 different areas in the Netherlands.
Eligible study subjects were identified using DBC codes, which is
the standardized accounting system for hospital care based on
diagnostic groups in The Netherlands [9]. In each hospital one
neurologist reviewed the medical files of all subjects identified with
DBC codes 0501 (PD) or 0502 (other extrapiramidal disorders)
between January 2006 to December 2011. Subjects with an initial
diagnosis before January 2006 or initially diagnosed elsewhere and
referred to one of the participating centers for follow-up care or
second opinion were excluded. Diagnoses included were: Parkin-
son disease, Progressive supranuclear palsy, Multiple system
atrophy, Vascular Parkinsonism, Corticobasal degeneration and
Dementia with Lewy bodies. For each included case, two matched
controls were selected from individuals who attended the same
departments of neurology within the same specified time-frame
with DBC codes 0801 (median nerve neuropathy; ICD-10 G56.0
and G56.1), 0802 (ulnar nerve neuropathy; ICD-10 G56.2), 1203
(thoracic and lumbar disc disease; ICD 10 G55.1, G54.3 and
G54.4) or 1204 (sciatica; ICD-10 M54.3 and M54.4). Controls
were incidence density matched to the cases on hospital, visiting
date (within 3 years of the cases diagnose year), sex and age
(interquartile range age difference: 6–33 days, max: 512 days). As
is standard in incidence density matching a control could serve as a
control for more than one case [10].
Telephone interview
Cases and controls were contacted via an invitation letter
containing study information and a reply form for giving informed
consent or to decline study participation. Non-responders were
sent a reminder after one month, and one phone call attempt was
performed after another month. Cases and controls were informed
that the study objective was to study risk factors for neurological
disorders, without specification. In a standardized computer-
assisted telephone interview, participants were interviewed by one
of three trained interviewers. The questionnaire contained a
complete residential and occupational history, questions about
selected dietary items, anthropometric measures and a medical
history. Detailed questions about smoking behavior were asked to
those reporting to have smoked more than 100 cigarettes during
their lifetime. The questions about smoking covered start and final
year of cigarette smoking and estimated amount of cigarettes
smoked in 10 year periods. In addition, information on cigar or
pipe smoking was obtained. Alcohol and coffee consumption was
ascertained as glasses or cups per week at current age and at the
age of 20, 40 and 60. For alcohol consumption information on
binge drinking was obtained (i.e. 5 or more alcohol consumptions
per occasion at least once a month). A typical telephone interview
lasted 30 to 45 minutes.
Exposure data
Smoking duration was defined as the number of years from start
of smoking until year of diagnosis or year of smoking cessation,
corrected for years not smoked in between. For former smokers
time-since-cessation was defined as year of diagnosis minus year of
smoking cessation. Intensity was defined as the average amount of
cigarettes per day in the period of smoking. Total smoking was
expressed as pack-years and calculated by dividing the intensity by
20 multiplied by the duration. Duration and intensity of alcohol
and coffee consumption were estimated with the information on
current consumption and consumption at the ages of 20, 40, and
60 (if relevant). Cumulative alcohol and coffee consumption was
calculated as consumption-years by multiplying the average
amount of consumptions per day with the estimated number of
years of consumption.
Statistical analysis
Due to the limited number of subjects with another Parkinson-
ism than PD (n= 40) we restricted our analyses to confirmed cases
of PD (n= 444).
We estimated main effects (odds ratios (OR) and 95%
confidence intervals (CI)) for total smoking, smoking intensity
(cigarettes per day), time since cessation, total alcohol consump-
tion, alcohol intensity (drinks per day), binge drinking (.4 drinks
per day), total coffee consumption, and coffee intensity (drinks per
day) with a conditional logistic regression model. Never users
constituted the reference categories while users were divided based
on the quartiles of the exposure distribution among the controls.
The number of never users for coffee consumption was low
(n= 38) and therefore the first quartile of coffee consumption
(including the never users) was used as the reference category.
Table 1. General Characteristics of Parkinson Disease Cases and Hospital Controls.
Cases Controls
(n =444) (n =876)
Men, No (%) 281 (63.3) 557 (63.6)
Age at interview, median (range) 68 (34–91) 68 (34–90)
Age at diagnosis, median (range) 67 (34–90) -
Higher educationa, No. (%) 268 (60.5) 477 (54.5)
Ever smoking cigarettes, No. (%) 237 (53.4) 633 (72.3)
Ever regular coffee consumptionb, No. (%) 427 (96.2) 855 (97.7)
Ever regular alcohol consumption, No. (%) 340 (76.6) 679 (77.5)
aInformation on education was missing for one case.
bInformation on coffee consumption was missing for one control.
doi:10.1371/journal.pone.0095297.t001
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To investigate the potential modification of the relationship
between total smoking and PD by intensity, duration and/or time-
since-cessation of smoking, we applied an inverse excess OR
model for total smoking, including modifying functions for
smoking intensity or duration and time-since-cessation. The
models described in this manuscript fall within a general
framework for flexible modeling of the effects of intensity,
duration, and time since exposure [8].
The model can be described as:
1
OR
~1zf (PCS)| exp (g(ICS)zh(TSC)) or
1
OR
~1zf (PCS)| exp (g(DCS)zh(TSC))
Where f(PCS) is a function of total pack-years of cigarette
smoking modified by a function of smoking intensity g(ICS) or
smoking duration g(DCS) and a function of time-since-cessation
h(TSC). Because PCS is defined as ICS*DCS, models 1 and 2
yield a similar inference. f(PCS), g(ICS), g(DCS) and h(TSC) were
included as linear function or as three-knot restricted cubic spline
(knots located at the 20th, 50th, and 80th percentile). To compare
the relative importance of duration, intensity, and time-since-
cessation of cigarette smoking, model fit was evaluated based on
the Akaike information criterion (AIC).
These models were fitted using the NLMIXED procedure in
SAS v 9.2 (SAS Institute Inc., Cary, NC). Bootstrapped 95%
confidence intervals were estimated via 100 bootstrap replications
of the original data and taking the 2.5th and 97.5th percentiles of
the resulting distribution. For presentation purposes the 1/OR
were back-transformed to the OR.
In ancillary analyses we assessed the variation of ORs jointly by
total smoking and time-since-cessation, by conducting uncondi-
Table 2. Parkinson Disease and Cigarette Smoking: Conditional Logistic Regression Analysis on Data of Patients and Hospital
Controls.
Cases Controls Crude Adjusteda
No. (%) No. (%) OR (95% CI) OR (95% CI)
Total smoking (pack-years)
Never smokers 207 (46.6) 243 (27.7) 1 1
.0–7.8 86 (19.4) 161 (18.4) 0.58 (0.42–0.82) 0.58 (0.42–0.82)
.7.8–17.5 67 (15.1) 155 (17.7) 0.45 (0.32–0.65) 0.46 (0.32–0.66)
.17.5–29.4 45 (10.1) 160 (18.3) 0.28 (0.18–0.42) 0.28 (0.18–0.42)
.29.4–103 39 (8.8) 157 (17.9) 0.26 (0.17–0.40) 0.27 (0.18–0.42)
P value for trendb ,0.0001/0.0004 ,0.0001/0.0006
Smoking intensity (cigarettes/day)
Never smokers 207 (46.6) 243 (27.7) 1 1
.0–7.0 77 (17.3) 158 (18.0) 0.53 (0.37–0.75) 0.53 (0.38–0.76)
.7.0–12.7 54 (12.2) 159 (18.2) 0.37 (0.25–0.53) 0.37 (0.25–0.54)
.12.7–19.2 50 (11.3) 158 (18.0) 0.33 (0.23–0.49) 0.34 (0.23–0.51)
.19.2–60.0 56 (12.6) 158 (18.0) 0.38 (0.26–0.54) 0.39 (0.27–0.57)
P value for trendb ,0.0001/0.16 ,0.0001/0.20
Smoking duration (years)
Never smokers 207 (46.6) 243 (27.7) 1 1
.0–18 98 (22.1) 165 (18.8) 0.66 (0.48–0.91) 0.66 (0.48–0.91)
.18–28 56 (12.6) 152 (17.4) 0.37 (0.25–0.54) 0.36 (0.24–0.53)
.28–41 48 (10.8) 166 (18.9) 0.29 (0.19–0.43) 0.29 (0.20–0.44)
.41–66 35 (7.9) 150 (17.1) 0.24 (0.15–0.37) 0.25 (0.16–0.39)
P value for trendb ,0.0001/,0.0001 ,0.0001/,0.0001
Time-since-cessation (years)
Never smokers 207 (46.6) 243 (27.7) 1 1
.31–53 93 (20.9) 158 (18.0) 0.67 (0.47–0.95) 0.65 (0.46–0.93)
.19–31 68 (15.3) 147 (16.8) 0.52 (0.36–0.76) 0.53 (0.36–0.77)
.0–19 54 (12.2) 166 (18.9) 0.35 (0.24–0.51) 0.36 (0.25–0.52)
0 22 (5.0) 162 (18.5) 0.15 (0.09–0.24) 0.15 (0.09–0.25)
P value for trendb n.a./,0.0001 n.a./,0.0001
Abbreviations: OR = odds ratio, CI = confidence interval.
aThe adjusted model includes coffee consumption (in quartiles).
bThe first P value for trend was based on analyses with the exposure as a continuous variable including the persons from the reference category. The second p value for
trend was based on analysis whereby the persons from the reference category are excluded.
doi:10.1371/journal.pone.0095297.t002
Smoking and Parkinson Disease
PLOS ONE | www.plosone.org 3 April 2014 | Volume 9 | Issue 4 | e95297
tional logistic regression adjusted for the matching variables age,
sex and center. In these analyses we categorized total smoking and
time-since-cessation into quintiles and estimated ORs for crossed
categories. All ORs were estimated relative to never smokers. We
conducted unconditional rather than conditional logistic regres-
sion as case-control sets were broken due to the cross-categoriza-
tion.
Results
1,330 subjects with an initial diagnosis of Parkinsonism between
2006 and 2011 were identified. 1,220 (92%) of those were still alive
at time of recruitment of which 1,001 had a diagnosis of PD. Ten
current addresses were unknown, 530 persons declined participa-
tion and 192 did not reply. The number of successfully enrolled
cases was 488 of which 448 were diagnosed with PD. Participation
rate among PD cases was 45%. Among controls the participation
rate was 35%. For 12 PD cases only 1 suitable control was found.
For 4 PD cases no suitable controls were found and these were
consequently excluded from the analysis. Table 1 shows the
demographic characteristics of the 444 PD cases and 876 controls
(of which 779 were unique) included in the present analyses.
Cigarette smoking was inversely related with PD. 53% of the
cases were ever smoker as compared to 72% of the controls
(x2 = 45.7, P,0.0001). When including cigar and pipe smoking
these numbers changed only slightly to 57% and 75%, respec-
tively. At the moment of interview 4% of the cases and 15% of the
controls were still smoking cigarettes.
Table 3. Parkinson Disease and Coffee and Alcohol Consumption: Conditional Logistic Regression Analysis on Data of Patients and
Hospital Controls.
Cases Controlsa Crude Adjustedb
No. (%) No. (%) OR (95% CI) OR (95% CI)
Coffee consumption (Consumption-years)
0–97 128 (28.8) 220 (25.1) 1 1
.97–156 146 (32.9) 221 (25.3) 1.13 (0.84–1.53) 1.30 (0.95–1.77)
.156–214 90 (20.3) 216 (24.7) 0.70 (0.50–0.97) 0.79 (0.56–1.12)
.214–720 80 (18.0) 218 (24.9) 0.61 (0.43–0.87) 0.83 (0.57–1.21)
P value for trendc 0.0016/0.0060 0.33/0.28
Coffee intensity (consumptions/day)
0–2.1 129 (29.1) 223 (25.5) 1 1
.2.1–3.4 134 (30.2) 215 (24.6) 1.07 (0.79–1.45) 1.16 (0.85–1.59)
.3.4–4.7 103 (23.2) 218 (24.9) 0.79 (0.57–1.10) 0.92 (0.65–1.30)
.4.7–17.1 78 (17.6) 219 (25.0) 0.60 (0.42–0.85) 0.80 (0.55–1.16)
P value for trendc 0.0002/0.0020 0.10/0.12
Alcohol consumption (consumption-years)
Never drinkers 104 (23.4) 197 (22.5) 1 1
.0–21 93 (20.9) 170 (19.4) 1.05 (0.74–1.49) 1.10 (0.75–1.60)
.21–48 99 (22.3) 172 (19.6) 1.10 (0.77–1.56) 1.44 (0.99–2.11)
.48– 80 (18.0) 169 (19.3) 0.87 (0.60–1.27) 1.27 (0.84–1.91)
.87–457 68 (15.3) 168 (19.2) 0.75 (0.50–1.11) 1.28 (0.82–1.98)
P value for trendc 0.14/0.18 0.38/0.73
Alcohol intensity (Consumptions/day)
Never drinkers 104 (23.4) 197 (22.5) 1 1
.0–0.6 98 (22.1) 169 (19.3) 1.09 (0.77–1.55) 1.23 (0.85–1.78)
.0.6–1.2 96 (21.6) 169 (19.3) 1.08 (0.76–1.55) 1.37 (0.94–2.01)
.1.2–2 80 (18.0) 172 (19.6) 0.87 (0.60–1.26) 1.21 (0.80–1.81)
.2–17.1 66 (14.9) 169 (19.3) 0.72 (0.48–1.06) 1.13 (0.74–1.74)
P value for trendc 0.021/0.042 0.92/0.70
Regular binge drinking (.4 drinks/occasion)
At age 20 (n= 1.320) 130 (29.3) 240 (27.4) 1.14 (0.86–1.52) 1.45 (1.07–1.96)
At age 40 (n= 1.305) 118 (26.9) 258 (29.8) 0.85 (0.64–1.13) 1.11 (0.82–1.49)
At age 60 (n= 888) 53 (18.2) 122 (20.4) 0.84 (0.59–1.22) 1.03 (0.70–1.51)
Abbreviations: OR = odds ratio, CI = confidence interval.
aCoffee consumption information was missing for one control, and was thus excluded in analyses including coffee consumption.
bThe adjusted model includes smoking and/or coffee consumption (in quartiles).
cThe first P value for trend was based on analyses with the exposure as a continuous variable including the persons from the reference category. The second P value for
trend was based on analysis whereby the persons from the reference category are excluded.
doi:10.1371/journal.pone.0095297.t003
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Conditional logistic regression
We observed an inverse association between total pack-years of
smoking, longer smoking duration, and shorter time-since-
cessation and PD risk (table 2). For average smoking intensity,
we observed reduced ORs among the exposed, but no trend was
observed when limiting the analyses to ever smokers (P=0.20).
Crude ORs for high total and average daily coffee consumption
point towards a lower risk of PD (table 3), but were not statistically
significant after adjustment for smoking. Analyses conducted
among never smokers showed a similar non-significant trend for
coffee consumption (ORs for the three highest quartiles of total
coffee consumption among never smokers: OR=1.11 (95% CI:
0.55, 2.26), OR=0.97 (95% CI: 0.43, 2.16) and OR=0.75 (95%
CI: 0.34, 1.66)).
No association with total and average alcohol consumption and
PD risk was found (table 3). Binge drinking was not associated with
PD risk with a possible exception of binge drinking at age 20 for
which a significantly elevated OR was found after adjusting for
smoking (table 3).
Excess odds ratio models
An excess odds ratio model that included a spline function for
total smoking and a linear function for time-since-cessation
provided the best fit to our data (AIC: 886.2 compared to an
AIC of 900.0 for a model in which the modifying effect of time-
since-cessation and duration (or intensity) was set to zero).
Including a spline function for time-since-cessation did not further
improve model fit (AIC: 888.0). Similar, including an additional
modifying function for intensity or duration of smoking did not
improve model fit (AIC: 888.2 and 885.5, respectively).
In Figure 1 we show the marginal effect of total smoking and
time-since-cessation on PD risk from our ‘best’ model, maintaining
the other factor in the model at the median level. The plot in
figure 1A indicates that the risk of PD decreases with increasing
total smoking. Figure 1B indicates that the effect of total smoking
on the risk of PD decreases with increasing time-since-cessation.
Ancillary analyses using standard unconditional logistic regres-
sion analyses adjusted for age, sex and center corroborate our
findings for time-since-cessation from the excess odds ratio model.
ORs for time-since-cessation plotted within categories of total
smoking follow a pattern similar to the prediction of our excess
odds ratio model with ORs being lowest within categories of
higher total smoking and shorter time-since-cessation (Figure 2).
Discussion
In our hospital based case-control study, we found a strong
inverse association between cigarette smoking and Parkinson
disease, which is in correspondence with earlier studies. We also
observed some indication of a potential inverse relation between
total and average coffee consumption with PD, but no association
with alcohol consumption was found.
Applying a novel modeling method in which the effects of
modifying factors are conditioned on total exposure, we found that
time-since-cessation has a high impact on the association between
total smoking and PD risk. We did not observe effect modification
of the effect of total smoking and PD risk by intensity or duration
of smoking, indicating that smoking intensity and duration have a
similar contribution to reduction of PD risk. The later finding is
different from previous findings that smoking duration would be
more important than intensity [5,6].
The applied model in this study is different from previously
published models (6,7) in that it models the inverse OR, rather
than the OR itself. This modification accommodates the
assessment of a protective effect of total pack-years of smoking
on PD by avoiding restriction of the parameter estimation range of
function f(PCS) (OR.0). We checked the appropriateness of our
model specification by i) Inversion of case-control status in the
dataset and consequential adjustment of the likelihood function to
be able to use a standard excess OR model and ii) by fitting a
standard excess OR model that included a sufficiently flexible
function for f(PCS) to accurately assess the asymptotic protective
effect of pack-years of smoking [OR=1+f(PCS)6exp (g(ICS)+h
(TSC))]. Both analyses yielded essentially similar results as our
preferred less constrained inverse OR model.
Figure 1. The modifying effects of time-since-cessation on the relation between smoking and PD. The fitted excess OR model with a
spline function for total smoking and effect modification by time-since-cessation. 95% confidence intervals were estimated via 100 bootstrap
replications. A: The OR for different levels of total pack-years, plotted for 21 years-since-cessation. B: The OR for different levels of time-since-
cessation, plotted for 15 pack-years of total smoking.
doi:10.1371/journal.pone.0095297.g001
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Biological mechanisms through which PD is linked to smoking
include the nicotinic acetylcholine receptors, which trigger
downstream signaling molecules, possibly resulting in protection
or delay of the development and progression of PD via effects such
as decreased apoptosis, enhanced neuronal survival or modified
immune responsiveness [11,12]. Other possible non-receptor
Figure 2. Odds ratios and 95% confidence intervals for time-since-cessation within categories of total pack-years of smoking. A–E:
Ever smokers were divided according to quintiles of total-smoking and the effect of time-since-cessation within those groups was plotted. ORs were
located at the quintile-specific average time-since-cessation and based on unconditional logistic regression relative to never-smokers adjusted for
age, sex and center. The lines represent the predicted ORs and 95% confidence intervals for different levels of time-since-cessation based on the
excess OR model plotted for the quintile-specific average pack-years of total smoking.
doi:10.1371/journal.pone.0095297.g002
Smoking and Parkinson Disease
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mediated mechanisms of nicotine include modulation of mito-
chondrial complex I activity or through its action as an antioxidant
[12].
As in any case-control study, we should keep in mind that our
results might also be (partly) explained by reverse causality. PD
patients have been described as having rigid, introverted and low-
tempered, and less novelty-seeking personality traits which may
lead to lower (or shorter) cigarette or alcohol consumption [13]. By
extension, low dopamine levels in individuals long before onset of
PD, leading to premorbid Parkinsonian personality traits [14],
might have a similar effect. However, many of the studies
investigating premorbid personality traits have methodological
deficiencies, which make interpretation difficult [15]. Of note,
imaging studies have shown nigrostriatal dopaminergic neuronal
loss starting to increase less than 10 years before onset of clinical
symptoms, suggesting a limited impact on cigarette and alcohol
consumption behavior earlier in life [16].
The inverse relationship between smoking and PD could also be
the result of a genetic factor related to both smoking behavior and
the chance of developing PD, but this hypothesis was not
supported by twin studies [17,18].
Our finding of a relationship between PD risk and time-since-
cessation provides some support for a true causal effect, as in the
case of reverse causality no direct association with time-since-
cessation would be expected. Some of the effect observed for time-
since-cessation might in fact be due to smoking duration, as most
participants in our study started smoking at a similar age (around
18) and consequently smoking duration and time-since-cessation
are inversely correlated (Pearson correlation coefficient: 20.75).
However, in a model including modifying factors for both smoking
duration and time-since-cessation a strong effect for time-since-
cessation, and not for duration, was observed, indicating the
observed effect is most likely due to time-since-cessation. In
addition, we did not observe a clear increase in the number of
cases quitting smoking as a consequence of disease onset in the
years before diagnosis (results not shown). As such, results from our
analyses of smoking behavior in the aggregate are supportive of a
causal protective effect of smoking that diminishes after quitting
smoking.
We also observed an inverse exposure dependent association
with total coffee consumptions and the average number of
consumptions per day and the risk of PD. These associations
were however not statistically significant in models adjusted for
smoking or in analyses limited to never smokers. Coffee has been
shown to be inversely related to PD risk in three meta-analyses
[2,19,20] and can be explained biologically by the idea that
caffeine in coffee is neuroprotective [21]. However, given the
relatively large impact of the adjustment by smoking on the
observed ORs we cannot rule out that the observed effect is due to
residual confounding by smoking.
Contrary to what has been suggested in the literature [22], we
did not observe an inverse association with alcohol consumption in
our study. We did observe a positive association with PD for
regular binge drinking at age 20, suggesting that drinking high
amounts of alcohol at a young age may increase the risk for PD.
Given that this could be a chance finding this result should be
interpreted with caution and needs replication.
A limitation of our study is the low participation rate. The
participation was lower among women (for cases 40%) than men
(49%), and depended on age. Under the age of 70, the
participation of cases was 66%. Sensitivity analysis restricted to
persons under age 70 showed similar results as when including all
participants (data not shown). About 50% of the non-participants
provided a reason for their decline. Health related reasons were
reported most frequently, but compared to cases, more controls
reported to be not interested.
Another possible limitation of our study is that controls were
selected from the same neurology departments as the cases and
that the underlying disease mechanism for these non-neurode-
generative conditions may share some characteristics with PD.
Repeating the analyses leaving out one control group at a time
(based on DBC codes), resulted in almost identical results,
suggesting that the results are not driven by one specific control
group adding to the validity of our results.
In conclusion, in a case-control study of 444 recently diagnosed
PD patients and 876 controls, we found an inverse association of
cigarette smoking and coffee consumption but not of alcohol
consumption with the risk of PD. In the association with smoking,
total smoking and time-since-smoking cessation appear to drive
PD risk. No effect modification of total smoking and PD risk by
either the intensity or the duration of smoking was observed,
indicating that both aspects have an equal contribution to the
reduction of PD risk.
These results provide some further insights into the etiology of
PD and may support the usefulness of randomized controlled trials
investigating the possibility that administering nicotine or nicotine-
mimicking drugs to PD patients might be effective in delaying
disease progression.
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